Cu(II)ATSM
Tier C — Watch / tradeCu(II)ATSM
Targets：Not applicable
Indications (approved)：Rectal cancer, Cervical cancer, Parkinson's disease, 运动神经元病, Amyotrophic lateral sclerosis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| Cu(II)ATSM | 213531-97-6 | - |
| Cu(II)ATSM-001 | 6610-29-3 | N-methylhydrazinecarbothioamide |
| Cu(II)ATSM-002 | 21983-72-2 | 3,3-dimethoxybutan-2-one |
| Cu(II)ATSM-003 | 2114324-41-1 | (E)-2-(3,3-dimethoxybutan-2-ylidene)-N-methylhydrazine-1-carbothioamide |
| Cu(II)ATSM-004 | 126971-40-2 | (E)-N-methyl-2-(3-oxobutan-2-ylidene)hydrazine-1-carbothioamide |
| Cu(II)ATSM-005 | 63618-91-7 | (2E,2'E)-2,2'-(butane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide) |
Frequently asked questions
What are the approved indications of Cu(II)ATSM?
Approved indications include: Rectal cancer, Cervical cancer, Parkinson's disease, 运动神经元病, Amyotrophic lateral sclerosis.
When does the Cu(II)ATSM patent expire?
No public expiry year is available for Cu(II)ATSM yet; this page updates once verified.
How many synthesis routes are recorded for Cu(II)ATSM?
1 synthesis routes are recorded; the shortest is 4 steps with 0.07 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Cu(II)ATSM intermediates?
All intermediates in Cu(II)ATSM routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Cu(II)ATSM intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21